Pfenex's - PFNX market analysis on 27th November 2020

Transaction Date	Recipient	Shares	Type	Price	Value
30th September 2020	Management, Llc Newtyn	3,850,000	Disposition due to a tender of shares in a change of control transaction	$0.00
30th September 2020	Asset Management Lp Weiss	801,424	Disposition due to a tender of shares in a change of control transaction	$12.00	$9,617,088.00
29th September 2020	Asset Management Lp Weiss	100,000	Open or private sale	$12.74	$1,273,580.00
16th June 2020	Patrick K. Lucy	770	Exercise of derivative	$3.38	$2,602.60
16th June 2020	Patrick K. Lucy	770	Open or private sale	$10.23	$7,873.33
2nd March 2020	Patrick K. Lucy	17,151	Open or private sale	$11.24	$192,706.92
2nd March 2020	Patrick K. Lucy	17,151	Exercise of derivative	$3.38	$57,970.38
27th November 2019	Patrick K. Lucy	3,000	Open or private sale	$10.03	$30,104.40
16th September 2019	Patrick K. Lucy	250	Open or private sale	$10.01	$2,502.50
16th September 2019	Patrick K. Lucy	1,800	Open or private sale	$10.00	$18,000.00

Pfenex

Pfênex, Inc. engages in the research, development, and commercialization of pharmaceutical products. The company was founded on November 19, 2009 and is headquartered in San Diego, CA.

Ticker: PFNX

Sector: Health Technology

Industry: Biotechnology

SEC Central Index Key (CIK): 1478121

Employees: 81

Exchange: NYSE American

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis